UBS Group’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.79M | Sell |
80,350
-40,419
| -33% | -$1.91M | ﹤0.01% | 3292 |
|
|
2025
Q1 | $4.72M | Buy |
120,769
+92,851
| +333% | +$3.63M | ﹤0.01% | 3002 |
|
|
2024
Q4 | $1.51M | Buy |
27,918
+21,578
| +340% | +$1.17M | ﹤0.01% | 3927 |
|
|
2024
Q3 | $320K | Buy |
6,340
+3,073
| +94% | +$155K | ﹤0.01% | 4370 |
|
|
2024
Q2 | $144K | Sell |
3,267
-11,485
| -78% | -$505K | ﹤0.01% | 4778 |
|
|
2024
Q1 | $741K | Buy |
14,752
+14,111
| +2,201% | +$709K | ﹤0.01% | 3783 |
|
|
2023
Q4 | $38.7K | Sell |
641
-484
| -43% | -$29.2K | ﹤0.01% | 5489 |
|
|
2023
Q3 | $64.1K | Buy |
+1,125
| New | +$64.1K | ﹤0.01% | 5002 |
|
|
2023
Q2 | – | Sell |
-7,960
| Closed | -$170K | – | 8184 |
|
|
2023
Q1 | $170K | Sell |
7,960
-65,428
| -89% | -$1.4M | ﹤0.01% | 4466 |
|
|
2022
Q4 | $771K | Sell |
73,388
-2,276
| -3% | -$23.9K | ﹤0.01% | 3339 |
|
|
2022
Q3 | $587K | Buy |
75,664
+2,004
| +3% | +$15.5K | ﹤0.01% | 3233 |
|
|
2022
Q2 | $387K | Buy |
73,660
+71,968
| +4,253% | +$378K | ﹤0.01% | 3517 |
|
|
2022
Q1 | $19K | Buy |
+1,692
| New | +$19K | ﹤0.01% | 6471 |
|
|
2021
Q3 | – | Sell |
-374
| Closed | -$4K | – | 8608 |
|
|
2021
Q2 | $4K | Buy |
+374
| New | +$4K | ﹤0.01% | 7570 |
|